These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19920919)

  • 1. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases.
    Polascik TJ
    Drug Des Devel Ther; 2009 Sep; 3():27-40. PubMed ID: 19920919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
    Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
    Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "The use of bisphosphonates to treat skeletal complications in solid tumours".
    D'Oronzo S; Wood S; Brown JE
    Bone; 2021 Jun; 147():115907. PubMed ID: 33676057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors.
    Major PP; Cook RJ; Chen BL; Zheng M
    Support Cancer Ther; 2005 Jul; 2(4):234-40. PubMed ID: 18628179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
    Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
    Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
    Wellington K; Goa KL
    Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of bone metastases and bone pain with bisphosphonates.
    Lipton A
    Support Cancer Ther; 2007 Jan; 4(2):92-100. PubMed ID: 18632473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.